Public Awareness and Concern over Influenza Driving Growth in Vaccine Manufacturing Market: companiesandmarkets.com

LONDON--(BUSINESS WIRE)-- In 2007 the world vaccine market was worth nearly $24.5 billion and is forecast to achieve a valuation of over $52 billion by 2016, according to a new report available from companiesandmarkets.com. Historically the vaccine market was one of the lowest profit making pharmaceutical segments, but interest in the market has soared following the launch of Prevnar and Gardasilblockbuster vaccines returning revenues of over $1 billion per annum.

Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing
http://www.companiesandmarkets.com/Market-Report/manufacturing-of-vaccines-cell-culture-technology-gradually-replacing-egg-based-manufacturing-686514.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The ever-present threat and increasing public awareness of pandemic influenza are boosting global vaccine sales, which are expected to grow at a CAGR of 11.5% to 2016. Until recently the vaccine manufacturing market held limited interest for pharmaceutical companies, however global outbreaks of influenza and the subsequent spike in demand for vaccinations has captured their attention.

In the absence of market share-eroding, generic alternatives to vaccines, AstraZeneca and Pfizer have committed to the vaccine manufacturing business, hoping to benefit from strong revenue streams in advance of upcoming patent expiries which will have a marked effect on income.

The adoption of adjuvant technologies - used to enhance a vaccine’s ability to provoke a strong immune reaction - will drive profitability of the vaccine market even further, as novel delivery methods and safety features help to justify higher price points.

Vaccine manufacturers are looking to extend the capabilities of existing vaccines, developing new versions which can treat additional diseases. The Gardasil vaccine is being re-engineered to prevent nine strains of HPV rather than the original four, while Prevnar is undergoing development to attack thirteen serogroups instead of six. Extension strategies are proving an increasingly viable and popular technique for piggybacking off the success of an existing vaccine brand name.

The 79 page, September 2011 publication investigates the key vaccine manufacturing processes (egg based and cell culture based), explaining the technologies and processes used in vaccine manufacture. The report includes discusses market drivers/barriers, challenges, regulatory affairs and other important factors influencing the vaccine manufacturing industry.

Report Details:
http://www.companiesandmarkets.com/Market-Report/manufacturing-of-vaccines-cell-culture-technology-gradually-replacing-egg-based-manufacturing-686514.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Mike King
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Infectious Diseases  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.